

PERSONAL INFORMATION



Marina Martello

📍 29, Via Monte di Sopra, Dozza 40060 (BO) - Italy

☎ 0542-695660 📠 338-1852581

✉ marina.martello2@unibo.it 📄 CF: MRT MRN 83 R69 C265J

🆔 <https://orcid.org/0000-0001-8196-8707>

🌐 Web of Science Researcher ID: AAB-9369-2022

🐦 Twitter: @marinamartello

📅 Date and Place of birth 29/10/1983, Castel San Pietro Terme (BO) | 🇮🇹 Nationality Italian

JOB POSITION **Post-doctoral fellow**

WORK EXPERIENCES

2026 Post-doctoral fellow

Institute of Hematology and Oncologic Sciences "L. and A. Seràgnoli", University of Bologna, IRCCS S. Orsola, Bologna – Laboratory of Molecular Biology, Prof.ssa Elena Zamagni

Translational research on Lymphoproliferative diseases, particularly focusing on Multiple Myeloma genomic and immunophenotypic characterization and minimal residual disease analyses, by means the most innovative approaches such as liquid biopsy and artificial intelligence

2023-2025 Fixed-term Researcher SSD MEDS-09/B DIMEC – University of Bologna

2019 Post-doctoral fellow on the project AIRC IG-2019: "StreaMMing: the dynamics of Multiple Myeloma minimal residual disease in the peripheral blood stream" - Institute of Hematology and Oncologic Sciences "L. and A. Seràgnoli", Bologna

2017-2018 Post-doctoral fellow on the project: "Global analysis of plasma cell differentiation stages and the role of Hedgehog pathway in Multiple Myeloma patients: a biological and clinical perspective" - Institute of Hematology and Oncologic Sciences "L. and A. Seràgnoli", Bologna

2015-2016 Post-doctoral fellow on the project: "High-resolution molecular characterization of Acute Myeloid Leukemia: towards a precision medicine approach" - Institute of Hematology and Oncologic Sciences "L. and A. Seràgnoli", Bologna

2014 Post-doctoral fellow on the project: "Study of clonal evolution in Multiple Myeloma through genomic characterization of cellular ecosystem" - Institute of Hematology and Oncologic Sciences "L. and A. Seràgnoli", Bologna

2007-2008 Trainee at the Industrial Microbiology Laboratory, University of Bologna - Prof. Brigidi. Main activities: To develop a DNA microarray for the characterization of the diversity of human gut microbiota

2000 Trainee at ISTEA Institute – Ecophysiology of Fruit Trees, CNR – Consiglio Nazionale delle Ricerche. Main activities: Banking of rare cultures of fruit trees and studying the cure for pathological diseases of olive trees

EDUCATION AND TRAINING

2017-2018 International II level Master on Nutrition and Diet at Università delle Marche
Thesis title: "Influence of diet on the composition of gut microbiota and its implications in cancer".
Tutor: Prof. Battino M.

2016 Visiting fellow at Dana Farber Cancer Center (Boston, MA)
Selected scientist at the "Translational Workshop for Basic Scientists" organized by AACR, and visiting fellow at Dana Farber Cancer Center and Massachusetts General Hospital in Boston

2011-2013 PhD in Biomedical Sciences at University of Bologna
Thesis title: "The search for Multiple Myeloma Stem Cells: molecular characterization and self renewal mechanisms involved in the disease persistence". Tutor: Prof. Martinelli G.

2008-2010 Master degree cum laude in Pharmaceutical Biotechnology at University of Bologna
Thesis title: "Molecular characterization of CD138+ tumoral plasma cells of newly diagnosed patients with Multiple Myeloma by SNP array". Tutor: Prof. Capranico G

2003-2008 Bachelor degree in Molecular Biotechnology at University of Bologna
Thesis title: "Development of a DNA microarray for the characterization of human gut microbiota".
Tutor: Prof. Brigidi P.

PROJECTS

| | |
|-----------------------|--|
| PRIN-2022 | Title: “ RandoMMness: the heterogenous spatial distribution of Multiple Myeloma unveiled by liquid biopsy ” |
| EU Project | DT-TDS-04: AI for Genomics and Personalised Medicine, Title: “ GENOMED4ALL: Genomics and Personalized Medicine for all through Artificial Intelligence in Haematological Diseases ” |
| EU Project | Grant n. 101172872, “ Synthetic data generation framework for integrated validation of use cases and AI healthcare applications ” |
| AIRC-IG2018 | Title: “ StreaMMing: the dynamics of Multiple Myeloma minimal residual disease in the peripheral blood stream ” |
| AIRC-IG2014 | Title: “ Unravelling the impact of different treatment strategies on intra-clonal heterogeneity in Multiple Myeloma ” |
| BERLUCCHI 2014 | Title: “ Definition of a Multiple Myeloma (MM) panel for the characterization and optimal selection of MM patients ” |

HONOURS and AWARDS

| | |
|-------------|--|
| | National Scientific Habilitation on 05/E3 - BIOCHIMICA CLINICA E BIOLOGIA MOLECOLARE CLINICA until 14/03/2037 |
| | Registered to the FNOB – Federazione Nazionale Ordine Biologi (n. AA084102) since 2020 |
| | Participation to international and national congresses as a speaker |
| | Author, co-author and reviewer for international scientific journals |
| | Associate editor for Molecular Diagnostics and Therapeutics - specialty section of Frontiers in Molecular Biosciences since 2024 |
| | Guest editor of PLOS ONE Editorial Board since 2023 |
| | Member of European Society of Cancer Research (EACR) since 2020 |
| | Member of Italian Society of Hematology (SIE and SIES) since 2011 |
| | Member of European Hematology Association (EHA) since 2012 |
| | Member of EHA2026 Scientific Program Committee Advisory Board (SPC-AB) |
| | Associate Member of American Association of Cancer Research (AACR) since 2012 |
| 2021 | IMS Young Investigator Award for Exemplary Abstract, IMW 2021, Wien |
| 2019 | ASH abstract achievement award, 61st ASH Annual Meeting, Orlando |
| 2019 | EHA Travel grant - 24th European Hematology Congress, Amsterdam |
| 2019 | Early Career Award - 2nd How to Diagnose and Treat Myeloma, Berlin |
| 2018 | EHA Travel grant - 23th European Hematology Congress, Stockholm |
| 2015 | Rising Star award at the 15th International Myeloma Workshop, Rome |
| 2014 | AACR-Pezcoller Foundation Scholar-in-Training Award at AACR Meeting, San Diego |

EXTRA-ACADEMIC EDUCATION

| | |
|-------------|--|
| 2025 | Selected scientist at EHA TiF Preceptorship on Precision Hematology in Homburg, Germany |
| 2025 | Last GCP R3 training : 03/09/2025 |
| 2018 | Training promoted by Cytognos “ Analysis of MM MRD samples using the EuroFlow NGF methodology ” - Policlinico S. Orsola – Malpighi, Bologna |
| 2016 | Training course “ R for basic users ”, Università Studi Milano - Bicocca |
| 2014 | Training course “ Flow cytometry: methods and applications ”, Policlinico S. Orsola – Malpighi, Bologna |
| 2014 | Training course “ Introduction to the System Biology ” – Corso Alta Formazione, Università dell’Insubria, Prof M. Fasano |
| 2010 | Art&Science Workshop – in collaboration with Fondazione Marino Golinelli and MaMbo – Galleria d’Arte Moderna, Bologna |

Mother tongue Italian

Other language(s)

| | UNDERSTANDING | | SPEAKING | | WRITING |
|----------------|---------------|---------|--------------------|-------------------|---------|
| | Listening | Reading | Spoken interaction | Spoken production | |
| English | C1 | C1 | C1 | C1 | C1 |
| French | A2 | A2 | A2 | A2 | A2 |

Lab skills Minimal residual disease analysis by using Next-generation sequencing (Illumina and Ion Torrent platform), Immunosequencing with Adaptive Clonoseq method, Whole genome and exome sequencing, Targeted Gene Panel sequencing, Single cell sequencing, SNP array, Microarray for gene expression analysis, Digital PCR, RT-PCR for quantitative analysis, Flow cytometry

Job skills Group discussions, Lab meetings and Bioinformatic analysis of results. Active participation to international projects and European clinical trials.

Educational activities Faculty member for Master I livello “Management del paziente con Mieloma Multiplo”, Università degli Studi di Torino since 2019
Faculty member for Educational Stages on Multiple Myeloma sponsored by Takeda, Bristol-Myers Squibb, Sanofi Aventis, Janssen Pharmaceutical and GlaxoSmithKline since 2013
Comment on a scientific paper for FAD Blood online.it (January 2024)
A.A.: 2018/2019: Teaching on a behalf of Prof. Zamagni E. during the course “Genetica Onco ematologica e delle emopatie” SSD: MED15, and A.A.2024/2025: FIOLOGIA UMANA C. I. [cod. 31360] - FIOLOGIA DEGLI ORGANI E DEGLI APPARATI [cod. 30766] - [Modulo 2]

Digital skills

| SELF-ASSESSMENT | | | | |
|------------------------|---------------|------------------|-------------|-----------------|
| Information processing | Communication | Content creation | Safety | Problem solving |
| Independent | Independent | Independent | Independent | Independent |

- R as a basic user
- good command of office suite (word processor, excel, access, power point)
- good command of photo and video editing software

SELECTED PUBLICATIONS

- Martello M, Oliva S et al., Next Generation Flow and Next Generation Sequencing for Measurable Residual Disease assessment in Multiple Myeloma Patients: A Real-Life Italian Multicenter Harmonization Experience, Cancer medicine Feb 2026, DOI: 10.1002/cam4.71678
- Mina R, Antonioli E, Barilà G, Bolli N, Botta C, Furlan A, Liberatore C, Martello M, Moré S, Oliva S, Rossini B, Saraci E, Solimando AG, Storti P, Zamagni E. Undetectable Minimal Residual Disease in Multiple Myeloma: Bridging the Gap Between Clinical Trials and Real-life Application. Clinical Lymphoma Myeloma and Leukemia, Jan 2026
- Talarico M, Barbato S, Maisnar V, Delimpasi S, Puppi M, Rizzello I, Pantani L, Tacchetti P, Martello M, Vigliotta I, Terragna C, Cavallo M, Zamagni E, Mancuso K. Exceptional long-term responses from OCEAN and HORIZON trials: melphufen-dexamethasone as an expansion of treatment options for relapsed/refractory multiple myeloma in the era of new immunotherapies? J Cancer Res Clin Oncol. 2025 Oct 9;151(11):288. doi: 10.1007/s00432-025-06326-3. PMID: 41065854; PMCID: PMC12511461.
- Poletti A, Taurisano B, Mazzocchetti G, Lionetti M, Martello M, Vuong VM, Solli V, Marzocchi G, Maeda A, Vigliotta I, Borsi E, Armuzzi S, Pistis I, Marella A, Fabris S, Tacchetti P, Mancuso K, Rizzello I, Pantani L, Testoni N, Cavallo M, Zamagni E, Bolli N, Terragna C. Unique molecular assay (UMA): a next-generation sequencing targeted panel for efficient and comprehensive genomic profiling and risk stratification of multiple myeloma. Haematologica. 2025 May 15. doi: 10.3324/haematol.2025.287559. Epub ahead of print. PMID: 40371906.
- D'Agostino, M., Martello, M., De Paoli, L. et al. Overview of 1q abnormalities in multiple myeloma: scientific opinions from Italian experts. Ann Hematol (2025). https://doi.org/10.1007/s00277-025-06212-5. PMID: 39945832
- Martello M, Solli V, Mazzocchetti G, Solimando AG, Bezzi D, Taurisano B, Kanapari A, Poletti A, Borsi E, Armuzzi S, Vigliotta I, Pistis I, Desantis V, Marzocchi G, Rizzello I, Pantani L, Mancuso K, Tacchetti P, Testoni N, Nanni C, Zamagni E, Cavallo M, Terragna C. High level of circulating cell-free tumor DNA at diagnosis correlates with disease spreading and defines multiple myeloma patients with poor prognosis. Blood Cancer J. 2024 Nov 28;14(11):208. doi: 10.1038/s41408-024-01185-6. PMID: 39609411; PMCID: PMC11605000.
- Vigliotta I, Solli V, Armuzzi S, Martello M, Poletti A, Taurisano B, Pistis I, Mazzocchetti G, Borsi E, Pantani L, et al. Circulating Multiple Myeloma Cells (CMMCs) as Prognostic and Predictive Markers in Multiple Myeloma and Smoldering MM Patients. Cancers 2024, 16, 2929. https://doi.org/10.3390/cancers16172929
- Borsi E, Vigliotta I, Poletti A, Mazzocchetti G, Solli V, Zazzeroni L, Martello M, Armuzzi S, Taurisano B, Kanapari A, Pistis I, Zamagni E, Pantani L, Rocchi S, Mancuso K, Tacchetti P, Rizzello I, Rizzi S, Dan E, Sinigaglia B, Cavallo M, Terragna C. Single-cell DNA sequencing reveals an evolutionary pattern of CHIP in transplant eligible Multiple Myeloma patients. Cells. 2024 Apr 9;13(8):657. doi: 10.3390/cells13080657.
- Terragna, C., Poletti, A., Solli, V., Martello, M., Zamagni, E., Pantani, L., ... Cavallo, M. (2024). Multi-dimensional scaling techniques unveiled gain1q&loss13q co-occurrence in Multiple Myeloma patients with specific genomic, transcriptional and adverse clinical features. Nat Commun, 15(1), 1551. doi:10.1038/s41467-024-45000-z
- Borsi E, Mazzocchetti G, Dico AF, Vigliotta I, Martello M, Poletti A, Solli V, Armuzzi S, Taurisano B, Kanapari A, Pistis I, Zamagni E, Tacchetti P, Pantani L, Mancuso K, Rocchi S, Rizzello I, Cavallo M, Terragna C. High levels of CRBN isoform lacking IMiDs binding domain predicts for a worse response to IMiDs-based upfront therapy in newly diagnosed myeloma patients. Clin Exp Med. 2023 Oct 10. doi: 10.1007/s10238-023-01205-y. Epub ahead of print. PMID: 37815734. IF: 5.057.
- Mancuso K, Zamagni E, Solli V, Gabrielli L, Leone M, Pantani L, Rocchi S, Rizzello I, Tacchetti P, Ghibellini S, Favero E, Ursi M, Talarico M, Barbato S, Kanapari A, Bigi F, Puppi M, Terragna C, Borsi E, Martello M, Poletti A, Scotà A, Nepoti G, Ruffini B, Lazzarotto T, Cavallo M. Long term follow-up of humoral and cellular response to mRNA-based vaccines for sars-CoV2 in patients with active Multiple Myeloma. Frontiers in Oncology, Volume 13 - 2023 | doi: 10.3389/fonc.2023.1208741. IF: 6.244
- Martello M, Solli V, Termini R, Kanapari A, Remondini D, Borsi E, Poletti A, Armuzzi S, Taurisano B, Vigliotta I, Mazzocchetti G, Merlotti A, Zamagni E, Tacchetti P, Pantani L, Rocchi S, Rizzello I, Mancuso K, Cavallo M, Terragna C. Identification of a Maturation plasma cell index through a highly sensitive droplet PCR assay gene expression signature validation in newly diagnosed Multiple Myeloma patients. International Journal of Molecular Sciences Oct 2022. IF: 6.208
- Vigliotta I, Armuzzi S, Barone M, Solli V, Pistis I, Borsi E, Taurisano B, Mazzocchetti G, Martello M, Poletti A, Sartor C, Rizzello I, Pantani L, Tacchetti P, Papayannidis C, Mancuso K, Rocchi S, Zamagni E, Curti A, Arpinati M, Cavallo M, Terragna C. The ALLgorithmMM: How to define the hemodilution of bone marrow samples in lymphoproliferative diseases. Front Oncol. 2022 Oct 6;12:1001048. doi: 10.3389/fonc.2022.1001048. PMID: 36276072; PMCID: PMC9582597. IF: 5.738
- Martello M. NEW GENOMIC, TRANSCRIPTOMIC AND CELLULAR RISK FACTORS IN MULTIPLE MYELOMA. Haematologica, Mar 2022 107, pp.5-6. ISSN:0390-6078
- Martello M, Poletti A, Borsi E, Solli V, Dozza L, Barbato S, Zamagni E, Tacchetti P, Pantani L, Mancuso K, Vigliotta I, Rizzello I, Rocchi S, Armuzzi S, Testoni N, Marzocchi G, Martinelli G, Cavallo M, Terragna C. Clonal and subclonal TP53 molecular impairment is associated with prognosis and progression in multiple myeloma. Blood Cancer J. 2022 Jan 26;12(1):15. doi: 10.1038/s41408-022-00610-y. PMID: 35082295; PMCID: PMC8791929. IF: 11.037
- G. Mazzocchetti, A. Poletti, V. Solli, E. Borsi, M. Martello, I. Vigliotta, S. Armuzzi, B. Taurisano, E. Zamagni, M. Cavallo, C. Terragna. BoBafit: A copy number clustering tool designed to refit and recalibrate the baseline region of tumors' profiles. Computational and Structural Biotechnology Journal, Volume 20, 2022, Pages 3718-3728, ISSN 2001-0370, https://doi.org/10.1016/j.csbj.2022.06.062. IF: 7.271
- Broccoli A, Terragna C, Nanni L, Martello M, Armuzzi S, Agostinelli C, Morigi A, Casadei B, Pellegrini C, Stefoni V, Sabatini E, Argnani L, Zinzani PL. Droplet digital polymerase chain reaction for the assessment of disease burden in hairy cell leukemia. Hematol Oncol. 2021 Oct 15. doi: 10.1002/hon.2932. Epub ahead of print. PMID: 34653277. IF: 5.271
- Rocchi S, Tacchetti P, Pantani L, Mancuso K, Rizzello I, di Giovanni Bezzi C, Scalse M, Dozza L, Marzocchi G, Martello M, Barilà G, Antonioli E, Staderini M, Buda G, Petrini M, Cea

- M. Quaresima M, Furlan A, Bonalumi A, Cavo M, Zamagni E. **A real-world efficacy and safety analysis of combined carfilzomib, lenalidomide, and dexamethasone (KRd) in relapsed/refractory multiple myeloma.** *Hematol Oncol.* 2020 Oct 21. doi: 10.1002/hon.2820. Epub ahead of print. PMID: 33085797. **IF: 5.271**
19. Forte D, Fanelli F, Mezzullo M, Barone M, Corradi G, Auteri G, Bartoletti D, **Martello M**, Ottaviani E, Terragna C, Curti A, Pagotto U, Palandri F, Cavo M, Catani L. **Disease-Specific Derangement of Circulating Endocannabinoids and N-Acylethanolamines in Myeloproliferative Neoplasms.** *Int J Mol Sci.* 2020 May 11;21(9):3399. doi: 10.3390/ijms21093399. PMID: 32403407; PMCID: PMC7246996. **IF: 6.208**
 20. Bolli N, Genuardi E, Zicocheddu B, **Martello M**, Oliva S, Terragna C. **Next-Generation Sequencing for Clinical Management of Multiple Myeloma: Ready for Prime Time?** *Front Oncol.* 2020; 10:189. Published 2020 Feb 25. doi:10.3389/fonc.2020.00189. **IF: 5.738**
 21. Zicocheddu B, Biancon G, Bagnoli F, De Philippis C, Maura F, Rustad EH, Dugo M, Devecchi A, De Cecco L, Sensi M, Terragna C, **Martello M**, Bagratuni T, Kastiris E, Dimopoulos MA, Cavo M, Camiti C, Montefusco V, Corradini P, Bolli N. **Integrative analysis of the genomic and transcriptomic landscape of double-refractory multiple myeloma.** *Blood Adv.* 2020 Mar 10;4(5):830-844. doi: 10.1182/bloodadvances.2019000779. PMID: 32126144; PMCID: PMC7065476. **IF: 7.367**
 22. Mancuso K, Tacchetti P, Pantani L, Rocchi S, Rizzello I, Caratuzzolo I, De Cicco G, Fusco A, Testoni N, Terragna C, Marzocchi G, **Martello M**, Borsi E, Dozza L, Cavo M, Zamagni E. **Maintenance therapy with bortezomib and dexamethasone after autotransplantation for high-risk multiple myeloma.** *Bone Marrow Transplant.* 2020 Sep;55(9):1865-1867. doi: 10.1038/s41409-020-0844-2. Epub 2020 Feb 26. PMID: 32103147. **IF: 5.483**
 23. Romano A, Palumbo GA, Parrinello NL, Conticello C, **Martello M**, Terragna C. **Minimal Residual Disease Assessment Within the Bone Marrow of Multiple Myeloma: A Review of Caveats, Clinical Significance and Future Perspectives.** *Front Oncol.* 2019 Aug 20;9:699. doi: 10.3389/fonc.2019.00699. PMID: 31482061; PMCID: PMC6710454. **IF: 5.738**
 24. Borsi E, **Martello M**, Santacroce B, Zamagni E, Tacchetti P, Pantani L, Mancuso K, Rocchi S, Cavo M, Terragna C. **Treatment optimization for multiple myeloma: schedule-dependent synergistic cytotoxicity of pomalidomide and carfilzomib in vitro and ex vivo models.** *Haematologica.* 2018 Dec;103(12):e602-e606. doi: 10.3324/haematol.2017.186924. Epub 2018 Jul 19. PMID: 30026343; PMCID: PMC6269297. **IF: 9.941**
 25. Zannetti B. A., Tacchetti P., Pantani L., Gamberi B., Tosi P., Rocchi S., Cellini C., Ronconi S., Pezzi A., Mancuso K., Rizzello I., Caratuzzolo I., **Martello M.**, Dozza L., Cavo M. and Zamagni E. **Novel agent-based salvage autologous stem cell transplantation for relapsed multiple myeloma.** *Annals of hematology.* 2017;96(12):2071-8. **IF: 3.673**
 26. **Martello M**, Remondini D, Borsi E, Santacroce B, Procacci M, Pezzi A, Dico FA, Martinelli G, Zamagni E, Tacchetti P, Pantani L, Marzocchi G, Rocchi S, Zannetti BA, Mancuso K, Cavo M, Terragna C. **Opposite activation of the Hedgehog pathway in CD138+ plasma cells and CD138-CD19+ B cells identifies two subgroups of patients with Multiple Myeloma and different prognosis.** *Leukemia.* 2016 Apr 14. doi: 10.1038/leu.2016.77. PubMed PMID: 27074969. **IF:10.431**
 27. Tacchetti P, Cavo M, Rocchi S, Pezzi A, Pantani L, Brioli A, Testoni N, Terragna C, Zannetti BA, Mancuso K, Marzocchi G, Borsi E, **Martello M**, Rizzello I, Zamagni E. **Prognostic impact of serial measurements of serum-free light chain assay throughout the course of newly diagnosed multiple myeloma treated with bortezomib-based regimens.** *Leuk Lymphoma.* 2016 Jan 14:1-7. PubMed PMID: 26763357. **IF:2.891**
 28. Pantani L, Brioli A, Tacchetti P, Zannetti BA, Mancuso K, Rocchi S, **Martello M**, Rizzello I, Terragna C, Zamagni E, Cavo M. **Current and emerging triplet combination therapies for relapsed and refractory multiple myeloma.** *Expert Rev Hematol.* 2016 Mar;9(3):31523. doi:10.1586/17474086.2016.1127754. Epub 2015 Dec 28. PubMed PMID: 26634945. **IF:2.070**
 29. Terragna C, Remondini D, **Martello M**, Zamagni E, Pantani L, Patriarca F, Pezzi A, Levi G, Offidani M, Proserpio I, De Sabbata G, Tacchetti P, Cangialosi C, Ciambelli F, Viganò CV, Dico FA, Santacroce B, Borsi E, Brioli A, Marzocchi G, Castellani G, Martinelli G, Palumbo A, Cavo M. **The genetic and genomic background of multiple myeloma patients achieving complete response after induction therapy with bortezomib, thalidomide and dexamethasone (VTD).** *Oncotarget.* 2016 Mar 1;7(9):9666-79. doi: 10.18632/oncotarget.5718. PubMed PMID: 26575327. **IF:6.539**
 30. **Martello M**, Remondini D, Borsi E, Santacroce B, Procacci M, Dico AF et al., **Hedgehog pathway activation in CD138+ cells identifies a subtype of Multiple Myeloma patients with unfavourable outcome.** Rising Star Award at 15th International Myeloma Workshop 2015; *Clinical Lymphoma, Myeloma and Leukemia*, Volume 15, Supplement 3, e38. 57th ASH Annual Meeting, Publication number 2961, *Blood supplemental volume*, December 2015.
 31. Zamagni E, Nanni C, Mancuso K, Tacchetti P, Pezzi A, Pantani L, Zannetti B, Rambaldi I, Brioli A, Rocchi S, Terragna C, **Martello M**, Marzocchi G, Borsi E, Rizzello I, Fanti S, Cavo M. **PET/CT Improves the Definition of Complete Response and Allows to Detect Otherwise Unidentifiable Skeletal Progression in Multiple Myeloma.** *Clin Cancer Res.* 2015 Oct 1;21(19):4384-90. doi: 10.1158/1078-0432.CCR-15-0396. Epub 2015 Jun 15. PubMed PMID: 26078390. **IF: 8.722**
 32. **Martello M**, B.Santacroce, F.Dico, T.Haferlach, A.Kholmman, F.Mignone, I.Saggese, C.Accorsi, E.Borsi, E.Zamagni, P.Tacchetti, L.Pantani, A.Brioli, Beatrice Anna Zannetti, S.Rocchi, K.Mancuso, N.Testoni, G.Marzocchi, G.Ameli, A.Pezzi, M.Cavo, G.Martinelli and C. Terragna **A Long Tail of Sub-Clonal TP53 Mutations Emerged By Ultra-Deep Sequencing of Newly Diagnosed Multiple Myeloma (MM).** *Blood supplemental volume*, ASH annual meeting - Dec 2014.
 33. **Martello M**, Angela Flores Dico, Daniel Remondini, Giovanni Martinelli, Enrica Borsi, Barbara Santacroce, Lucia Pantani, Elena Zamagni, Paola Tacchetti, Annamaria Brioli, Beatrice Anna Zannetti, Katia Mancuso, Serena Rocchi, Nicoletta Testoni, Giulia Marzocchi, Gaia Ameli, Michele Cavo, Carolina Terragna **High-Throughput Molecular Profiling of Multiple Myeloma (MM) Clonotypic CD19+ B Cells Highlights Pathways Potentially Involved in the Disease Endurance.** *Blood supplemental volume*, ASH annual meeting - Dec 2014.
 34. Borsi E, Terragna C, Brioli A, Tacchetti P, **Martello M**, Cavo M. **Therapeutic targeting of hypoxia and hypoxia-inducible factor 1 alpha in multiple myeloma.** *Transl Res.* 2015 Jun;165(6):641-50. doi: 10.1016/j.trsl.2014.12.001. Epub 2014 Dec 11. Review. PubMed PMID: 25553605. **IF:5.030**
 35. Borsi E, Perrone G, Terragna C, **Martello M**, Zamagni E, Tacchetti P, Pantani L, Brioli A, Dico AF, Zannetti BA, Rocchi S, Cavo M. **HIF-1 α inhibition blocks the cross talk between multiple myeloma plasma cells and tumor microenvironment.** *Exp Cell Res.* 2014 Nov 1;328(2):444-55. doi: 10.1016/j.yexcr.2014.09.018. Epub 2014 Sep 26. PubMed PMID: 25257607. **IF:3.246**
 36. Tacchetti P, Terragna C, Galli M, Zamagni E, Petrucci MT, Pezzi A, Montefusco V, **Martello M**, Tosi P, Baldini L, Peccatori J, Ruggieri M, Pantani L, Lazzaro A, Elice F, Rocchi S, Gozzetti A, Cavaletti G, Palumbo A, Cavo M. **Bortezomib- and thalidomide-induced peripheral neuropathy in multiple myeloma: clinical and molecular analyses of a phase 3 study.** *Am J Hematol.* 2014 Dec;89(12):1085-91. doi: 10.1002/ajh.23835. Epub 2014 Sep 17. PubMed PMID: 25159313. **IF:3.789**
 37. Borsi E, Perrone G, Terragna C, **Martello M**, Dico AF, Solaini G, Baracca A, Sgarbi G, Pasquinelli G, Valente S, Zamagni E, Tacchetti P, Martinelli G, Cavo M. **Hypoxia inducible factor-1 alpha as a therapeutic target in multiple myeloma.** *Oncotarget.* 2014 Apr 15;5(7):1779-92. PubMed PMID: 24732040; PubMed Central PMCID: PMC4039126. **IF:6.359**
 38. Terragna C, Renzulli M, Remondini D, Tagliafico E, Di Raimondo F, Patriarca F, Martinelli G, Roncaglia E, Masini L, Tosi P, Zamagni E, Tacchetti P, Ledda A, Brioli A, Angelucci E, Testoni N, Marzocchi G, Gallieni P, Gozzetti A, **Martello M**, Dico F, Mancuso K, Cavo M. **Correlation between eight-gene expression profiling and response to therapy of newly diagnosed multiple myeloma patients treated with thalidomide-dexamethasone incorporated into double autologous transplantation.** *Ann Hematol.* 2013 Sep;92(9):1271-80. doi: 10.1007/s00277-013-1757-6. Epub 2013 May 10. PubMed PMID: 23660628. **IF:2.634**

According to art. 13 d. lgs. 30 june2003 n°196 and to art. 13 GDPR 679/16 (UE 2016/679) I give my consent to the personal data.

Bologna, 13/02/2026

In fede,
Dr. Marina Martello

